18
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Comparison of tiotropium bromide and combined ipratropium/salbutamol for the treatment of COPD: a UK General Practice Research Database 12-month follow-up study

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Aims:

          To compare the effectiveness of the long-acting anticholinergic, tiotropium with ipratropium/salbutamol in reducing the risk of exacerbations and COPD-related referrals in patients with COPD.

          Methods:

          Data were obtained from the General Practice Research Database (GPRD). Propensity score matching was used to balance prognostic covariates between treatment groups. Incidence rate ratios and 95% confidence intervals during a 12-month follow-up period were estimated.

          Results:

          4193 patients (3385, tiotropium; 808, ipratropium/salbutamol) in the GPRD met the inclusion/exclusion criteria. Patients treated with tiotropium had more severe COPD than patients treated with ipratropium/salbutamol. Following propensity score matching, 1222 tiotropium-treated patients and 633 ipratropium/salbutamol-treated patients were included in the final analysis. Incidence rate ratios (95% confidence intervals) were 0.74 (0.64–0.85; p=0.0086) for exacerbations and 0.57 (0.46–0.70; p=0.004) for COPD-related referrals/hospitalisations.

          Conclusions:

          Tiotropium is associated with a reduced risk of exacerbations and COPD-related referrals and hospitalisation compared to combined ipratropium/salbutamol in patients with COPD.

          Related collections

          Author and article information

          Journal
          Prim Care Respir J
          Prim Care Respir J
          Primary Care Respiratory Journal: Journal of the General Practice Airways Group
          Nature Publishing Group
          1471-4418
          1475-1534
          June 2008
          02 April 2008
          : 17
          : 2
          : 104-110
          Affiliations
          [1 ] Health Economics & Outcomes Research, Boehringer Ingelheim Limited , Bracknell, Berkshire, RG12 8YS, UK
          [2 ] Corporate Department of Medical Affairs, Boehringer Ingelheim Limited , Ingelheim, Germany
          [3 ] Professor of Primary Care Respiratory Medicine, Department of General Practice and Primary Care, University of Aberdeen , Scotland, UK
          Author notes
          [* ]Miss Jane Griffin, Health Economics & Outcomes Research, Boehringer Ingelheim Limited , Bracknell, Berkshire, RG12 8YS, UK. Tel: +44 1344 741 494 Fax: +44 1344 741 298 Email: jane.griffin@ 123456boehringer-ingelheim.com
          Article
          PMC6619881 PMC6619881 6619881 pcrj200824
          10.3132/pcrj.2008.00024
          6619881
          18385913
          5324115d-c7e6-457e-9867-766a9caf3fbf
          Copyright © 2008 General Practice Airways Group
          History
          : 23 January 2008
          : 19 February 2008
          : 11 March 2008
          Categories
          Original Research

          tiotropium,ipratropium/salbutamol,hospitalisation,general practice database,COPD

          Comments

          Comment on this article